行情

ADVM

ADVM

Adverum
NASDAQ

实时行情|Nasdaq Last Sale

11.72
+0.02
+0.17%
盘后: 11.72 0 0.00% 16:30 01/17 EST
开盘
11.94
昨收
11.70
最高
12.18
最低
11.46
成交量
115.77万
成交额
--
52周最高
16.38
52周最低
2.900
市值
7.57亿
市盈率(TTM)
-12.1716
分时
5日
1月
3月
1年
5年

分析师评级

7位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

ADVM 新闻

  • 一个时代的终结? 二十世纪福克斯电影公司改名了
  • 中国新闻网.2小时前
  • 日经:日本拟在2030年实现6G
  • 新浪科技.2小时前
  • 关店1300家,真维斯真得卖不动了?
  • 新浪科技-自媒体综合.3小时前
  • 达沃斯新浪财经早餐会:国际视野下的ESG中国实践
  • 新浪财经.3小时前

更多

所属板块

生物技术和医学研究
-0.16%
制药与医学研究
+0.06%

热门股票

名称
价格
涨跌幅

ADVM 简况

Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases. Adverum has a robust pipeline that includes product candidates designed to treat rare diseases alpha-1 antitrypsin (A1AT) deficiency and hereditary angioedema (HAE) as well as wet age-related macular degeneration (wAMD). Leveraging a next-generation adeno-associated virus (AAV)-based directed evolution platform, Adverum generates product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. It has collaboration agreements with Regeneron Pharmaceuticals to research, develop, and commercialize gene therapy products for ophthalmic diseases and Editas Medicine to explore the delivery of genome editing medicines for the treatment of inherited retinal diseases. Its core capabilities include clinical development and in-house manufacturing, specifically in process development and assay development.
展开

Webull提供Adverum Biotechnologies Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。